Combined modality treatment with full-dose chemotherapy and concomitant boost radiotherapy for advanced head and neck carcinoma

Détails

ID Serval
serval:BIB_F1B109E7527F
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Combined modality treatment with full-dose chemotherapy and concomitant boost radiotherapy for advanced head and neck carcinoma
Périodique
European Archives of Oto-Rhino-Laryngology
Auteur(s)
Kutter  J., Ozsahin  M., Monnier  P., Stupp  R.
ISSN
0937-4477 (Print)
Statut éditorial
Publié
Date de publication
01/2005
Volume
262
Numéro
1
Pages
1-7
Notes
Journal Article --- Old month value: Jan
Résumé
The purpose of this study was to evaluate the feasibility and efficacy of a treatment concept combining three cycles of full-dose chemotherapy (CT) with concomitant accelerated uninterrupted radiotherapy (RT). Twenty-three patients (median age: 54 years, range: 35-70) with locally advanced squamous cell carcinoma of the head and neck (SCCHN) were included. The primary tumor involved the hypopharynx (n=7), base of the tongue (n=10), nasopharynx (n=2) or upper esophagus (n=1) or its location was unknown (n=3). Treatment consisted of three cycles of chemotherapy (cisplatin 100 mg/m2 on day 1; 5-FU 1,000 mg/m2 per day for 5 days as a continuous infusion, preceded by amifostine 910 mg/m2), repeated every 3 weeks. Uninterrupted concomitant boost-accelerated RT (total dose of 70 Gy in 6 weeks) started together on day 1 of the second cycle. All but two patients received the full course of RT. Eighteen patients achieved complete remission (78%). At a median follow-up of 45 months the overall survival was 56% (95% c.i. 32-79%) and the loco-regional control 71% (95% c.i. 52-91%). Toxicity involved reversible renal insufficiency of > or = grade II in 9 patients (39%) and neutropenic fever in 9 patients (39%). All patients suffered from moderate to severe mucositis (grade II/III), and 19 patients presented cutaneous toxicity grade III. Concomitant boost-accelerated RT combined with concurrent full-dose cisplatin/5-FU chemotherapy and amifostine is feasible with manageable, although substantial, toxicity. The overall survival of 4 years is promising. Newer regimens causing less acute mucosal and skin toxicity are needed.
Mots-clé
Adult Aged Amifostine/therapeutic use Antineoplastic Combined Chemotherapy Protocols/therapeutic use Carcinoma, Squamous Cell/*drug therapy/pathology/*radiotherapy Cisplatin/therapeutic use Combined Modality Therapy Drug Administration Schedule Esophageal Neoplasms/*drug therapy/pathology/*radiotherapy Female Humans Hypopharyngeal Neoplasms/*drug therapy/pathology/*radiotherapy Male Middle Aged Nasopharyngeal Neoplasms/*drug therapy/pathology/*radiotherapy Neoplasm Staging Radiotherapy Dosage Tongue Neoplasms/*drug therapy/pathology/*radiotherapy
Pubmed
Web of science
Création de la notice
28/01/2008 9:39
Dernière modification de la notice
03/03/2018 22:38
Données d'usage